Browse the corpus

Glomus jugulare tumors are rare, slow-growing paragangliomas arising from the jugular foramen of the temporal bone. This activity reviews tumor origin, epidemiology, hereditary considerations, patterns of local invasion, and the clinical manifestations that commonly include hearing loss, pulsatile tinnitus, and lower cranial nerve dysfunction. Key diagnostic features are discussed, including characteristic otoscopic findings, audiologic testing, and the roles of diagnostic imaging studies in defining tumor extent, vascularity, and treatment planning. The activity also outlines classification systems used to guide management decisions and prognostication. Participants can expect an in-depth review of contemporary management strategies, including observation, surgical resection, embolization, external-beam radiotherapy, and stereotactic radiosurgery, with an emphasis on individualized, patient-centered decision-making. This activity for healthcare professionals is designed to enhance the learner's competence in recognizing glomus jugulare tumors, interpreting diagnostic findings, weighing risks and benefits of available therapies, and collaborating effectively within interprofessional teams to optimize outcomes and minimize morbidity. Objectives: Identify the clinical features of glomus jugulare tumors. Apply established classification systems to guide treatment planning in patients with glomus jugulare tumors. Select individualized, evidence-based treatment strategies that balance tumor control and functional preservation for patients with glomus jugulare. Collaborate on interprofessional team strategies to improve care coordination and outcomes in patients with glomus jugulare tumors. Access free multiple choice questions on this topic.

Glomus jugulare represents a rare, slow-growing neuroendocrine paraganglioma of the head and neck that arises within the jugular foramen and localizes to the jugular fossa of the temporal bone at the skull base.[1][2] Paragangliomas originate from neural crest–derived paraganglia and are typically benign. These tumors are also referred to as chemodectomas, with an estimated incidence reported as high as 1 to 3 per 100,000 people.[1][3] Paragangliomas fall into 2 categories, sympathetic and parasympathetic, with most head and neck paragangliomas, including glomus jugulare tumors, arising from the parasympathetic cells.[4] Within the head and neck, paragangliomas arise in multiple anatomic locations, including the carotid bifurcation as carotid body tumors, the superior vagal ganglion as glomus jugulare tumors, the auricular branch of the vagus nerve as glomus tympanicum tumors, and the inferior vagal ganglion as glomus vagale tumors. Recent literature uses the term temporal bone paraganglioma as a collective designation for tumors originating from the tympanic branch of the glossopharyngeal nerve and the auricular branch of the vagus nerve, previously termed glomus tympanicum.[5] Despite a typically indolent growth pattern, glomus tumors may cause substantial morbidity through mass effect, compression, and erosion of adjacent structures.[1] Management of glomus jugulare tumors remains complex due to marked hypervascularity, challenging anatomy, and frequent presentation at an advanced stage.[4]

Glomus jugulare tumors arise from the paraganglia cells located in the adventitia wall of the jugular bulb, within the jugular foramen. They grow slowly and are usually benign. However, due to their location, they can cause a mass effect with invasion and erosion of the temporal bone as they increase in size. Only 1% to 5% are malignant.[2] Approximately 80% of paragangliomas are sporadic, with the rest exhibiting a hereditary component.[4] Inherited forms present with earlier symptom onset and can be bilateral as well as functional; however, familial forms exhibit a lower malignancy rate than sporadic counterparts.[4]

The estimated annual incidence of glomus jugulare tumors has been reported to be about 0.07 per 100,000, or 1 case per 1.3 million people.[2] The median age at diagnosis is 56 (range of 44 to 69 years).[6] Female presentation is 3 to 6 times more common than male presentation.[7] Among head and neck paragangliomas, 44% to 48% are carotid body tumors, 16% to 24% are glomus jugulare, 20% are glomus tympanicum, and 8% are glomus vagale.[8][9][10]

Early-stage paragangliomas present with signs and symptoms related to their location. Specifically, most of these will be related to the involvement of the middle ear cleft. These neoplasms tend to spread through the hypotympanic air cells, around the jugular bulb, inferior petrosal sinus, and carotid artery into the jugular foramen and posterior cranial fossa.[4] They can also erode the floor of the hypotympanum and can, therefore, present as a middle ear mass. If an erosion of the tympanic membrane has occurred, they can also present as an aural mass or with otorrhagia. Further extension of the tumor through the facial recess can result in facial nerve encasement and paralysis.[4] Up to 1% to 3% of glomus tumors secrete catecholamines.[1] With high enough levels, pheochromocytoma-like symptoms may develop, resulting in systemic effects. Signs and symptoms of a hormonally active tumor include labile hypertension, increased heart rate, headache, excessive sweating, tremors, and facial flushing; these mandate a comprehensive evaluation.[4] A 24-hour urinary collection for catecholamines and metanephrines (or vanillylmandelic acid, a physiologic product of the breakdown of catecholamines) needs to be ordered in these cases. Plasma metanephrine testing can also be requested.

Round cells that occur in alveolus-like clusters/balls of 5 to 30 cells, called "zellballen." Nuclear pleomorphism is common, but mitoses are rare. Dense fibrous or myxoid stroma separates the cell clusters, and thin-walled, sinusoidal capillaries are widely present.[11]

Patients most commonly present with progressive hearing loss, pulsatile tinnitus, and manifestations of lower cranial nerve neuropathy.[2][4][7] These hallmark symptoms occur in up to 75% of affected individuals and often reflect tumor extension within the temporal bone and adjacent neurovascular structures. Auditory complaints frequently dominate the initial presentation, whereas pulsatile tinnitus reflects the lesion's hypervascularity. Lower cranial nerve deficits develop in up to 10% of cases and may produce a broad spectrum of neurological impairments, including facial palsy, dysphagia, hoarseness, shoulder weakness, and tongue deviation.[2][7][12] Facial paralysis remains uncommon during the natural progression of a glomus tumor and suggests invasion of the intersinuso-facial space.[13] Additional clinical features may include otalgia, otorrhea, and bleeding from the ear, particularly in cases with middle ear involvement or erosion of surrounding structures.

Otoscopic Examination Physical examination most often reveals a pulsatile, red mass in the middle ear, located behind an intact tympanic membrane.[7] The tympanic membrane may demonstrate prominent vascularity associated with an inferiorly based red mass, producing the characteristic rising sun appearance, commonly referred to as the rising sun sign. In some cases, the tympanic component of the tumor erodes into the external auditory canal, leading to otorrhagia.[7] Pneumatic insufflation serves as an additional bedside maneuver during otoscopic evaluation. In the presence of a glomus tumor, pneumatic pressure produces blanching of the tympanic membrane, a finding known as Brown's sign.[14] Audiologic Testing Audiologic evaluation includes pure-tone audiometry and speech audiometry to characterize the degree and pattern of hearing impairment and establish a baseline for ongoing assessment.[4] Computed Tomography High-resolution computed tomographic imaging of the head with fine cuts through the temporal bone may demonstrate osseous involvement. Tumor-related bone destruction often appears as irregular erosion, commonly described as a moth-eaten pattern.[4] Magnetic Resonance Imaging Magnetic resonance imaging (MRI) with intravenous contrast enhancement demonstrates an avidly enhancing lesion that typically extends from the jugular bulb into the middle ear. Untreated tumors frequently show posterior fossa and cervical extension. Prominent vascular flow voids create the classic salt-and-pepper appearance on T1- and T2-weighted sequences. MRI delineates tumor vascularity, neural foraminal spread, and multicentric disease and serves as the preferred initial imaging modality for suspected glomus jugulare tumors. On non–contrast-enhanced T1-weighted sequences, paragangliomas may appear hypointense with a speckled pattern, while gadolinium-enhanced sequences reveal intense enhancement related to marked hypervascularity.[4] Angiography

MRI delineates tumor vascularity, neural foraminal spread, and multicentric disease and serves as the preferred initial imaging modality for suspected glomus jugulare tumors. On non–contrast-enhanced T1-weighted sequences, paragangliomas may appear hypointense with a speckled pattern, while gadolinium-enhanced sequences reveal intense enhancement related to marked hypervascularity.[4] Angiography Angiography assists in differentiating paragangliomas from other skull base lesions and demonstrates the tumor blush and arterial supply, allowing identification of vessels amenable to embolization. The ascending pharyngeal artery is the primary feeding vessel, with additional contributions from the occipital artery, both of which arise from the external carotid artery.[4] Additional arterial supply may originate from branches of the internal carotid artery and the vertebrobasilar system, including the caroticotympanic artery and the posterior inferior cerebellar artery.[4] Balloon test occlusion studies aid in determining patient tolerance to potential occlusion of the petrous segment of the internal carotid artery.[15] Tumor Classifications The Fisch and Glasscock-Jackson classification systems remain the most widely used frameworks for staging glomus jugulare tumors based on anatomic location and extent of disease.[16][17][18] These grading systems inform treatment selection, including surgical and radiosurgical approaches, and assist in predicting clinical outcomes and the likelihood of recurrence.

Management Approaches Observation serves as a viable treatment strategy for glomus jugulare tumors, with studies showing that 65% of tumors remain stable and some even regress in size.[19] Approximately 40% demonstrate slow growth, averaging 0.9 mm per year.[20] When observation is chosen, patients require close follow-up with serial brain MRIs, both with and without intravenous contrast, to monitor tumor behavior and progression. Multiple therapeutic approaches aim to optimize local tumor control while minimizing treatment-related morbidity, yet managing glomus jugulare tumors remains challenging.[4] Controversy persists regarding the optimal treatment approach. Historically, management included surgical resection, external beam radiotherapy (EBRT), or a combination of both.[1] These interventions carry significant morbidity, prompting increased adoption of stereotactic radiosurgery (SRS).[1][21] Systematic reviews demonstrate comparable tumor control between EBRT, SRS, and surgical intervention in jugular paragangliomas, emphasizing the need to individualize treatment based on patient age, tumor extent, comorbidities, and functional status.[22] Surgical Therapy Surgical resection remains the preferred option for young, otherwise healthy patients, particularly when cranial nerve function is compromised. Preoperative embolization is typically performed 24 to 72 hours before surgery to reduce intraoperative blood loss.[15] Complete resection is achievable in approximately 80% of cases but may result in debilitating cranial neuropathies, with new postoperative deficits occurring in 60% of patients, often affecting cranial nerves IX, X, XI, and XII.[23] Subtotal resection has gained favor to reduce morbidity while improving symptom control.[20] Approximately 1% to 3% of glomus jugulare tumors secrete catecholamines, necessitating preoperative alpha-blockade with medications such as phenoxybenzamine initiated two weeks before surgery. Beta-blockers may be added later if required to control heart rate, but only after alpha-blockade is established to prevent hypertensive crises. Patients should also be counseled to increase fluid and salt intake to expand blood volume and offset hormone-related deficits.[1]

Surgical resection remains the preferred option for young, otherwise healthy patients, particularly when cranial nerve function is compromised. Preoperative embolization is typically performed 24 to 72 hours before surgery to reduce intraoperative blood loss.[15] Complete resection is achievable in approximately 80% of cases but may result in debilitating cranial neuropathies, with new postoperative deficits occurring in 60% of patients, often affecting cranial nerves IX, X, XI, and XII.[23] Subtotal resection has gained favor to reduce morbidity while improving symptom control.[20] Approximately 1% to 3% of glomus jugulare tumors secrete catecholamines, necessitating preoperative alpha-blockade with medications such as phenoxybenzamine initiated two weeks before surgery. Beta-blockers may be added later if required to control heart rate, but only after alpha-blockade is established to prevent hypertensive crises. Patients should also be counseled to increase fluid and salt intake to expand blood volume and offset hormone-related deficits.[1] Subtotal resection followed by adjuvant radiosurgery for residual tumor often achieves improved outcomes with lower morbidity and mortality.[24] Endoscopic assistance during surgery can facilitate smaller incisions and tailored trajectories, particularly for posterior fossa extensions. Advances in intraoperative nerve monitoring further support preservation of lower cranial nerve function. Radiation Therapy Radiation therapy plays an important role in bilateral glomus jugulare tumors or when surgical intervention is limited. Modalities include standard fractionated radiotherapy, delivered over multiple sessions, and stereotactic radiosurgery, which provides focused treatment in a single session while sparing critical structures within the temporal bone.[4] Radiation may serve as an adjunct to limited surgery or as a primary modality in patients who are poor surgical candidates or have bilateral disease, with tumor control rates up to 90%.[4][25] Systematic reviews and meta-analyses report tumor control in 92% of patients and symptom control in 93% when SRS is used, with an 8% complication rate.[26][27] Achieving local control of 90% or greater typically requires a median marginal dose of 15 Gy, ranging from 12 to 30 Gy.[6] Embolization Therapy

Radiation therapy plays an important role in bilateral glomus jugulare tumors or when surgical intervention is limited. Modalities include standard fractionated radiotherapy, delivered over multiple sessions, and stereotactic radiosurgery, which provides focused treatment in a single session while sparing critical structures within the temporal bone.[4] Radiation may serve as an adjunct to limited surgery or as a primary modality in patients who are poor surgical candidates or have bilateral disease, with tumor control rates up to 90%.[4][25] Systematic reviews and meta-analyses report tumor control in 92% of patients and symptom control in 93% when SRS is used, with an 8% complication rate.[26][27] Achieving local control of 90% or greater typically requires a median marginal dose of 15 Gy, ranging from 12 to 30 Gy.[6] Embolization Therapy Complete tumor obliteration using embolization alone proves difficult due to revascularization and offers minimal symptomatic relief.[28] Endovascular embolization functions primarily as a palliative measure.[4] Onyx embolization may be employed to manage persistent otorrhagia in unresectable tumors.[28] When used preoperatively, embolization can reduce operative duration and estimated blood loss.[4]

Differential diagnoses that should also be considered when evaluating patients with suspected glomus jugulare tumors include: Schwannoma of the lower cranial nerves Neuroma of the lower cranial nerves Glomus tympanicum Neck and head metastasis Bone metastasis Lymph node metastasis Carotid space meningioma Cholesteatoma Endolymphatic sac tumors Chordoma Chondrosarcoma Epidermoid Chronic mastoiditis Hemangiopericytoma Plasmacytoma Dural arteriovenous fistula Arteriovenous malformations High-riding jugular bulb Asymmetry of jugular foramen size Carotid artery dissection Carotid artery fenestration Aberrant carotid artery Tortuous internal carotid artery Fibromuscular dysplasia Idiopathic intracranial hypertension [29]

Recent series show a stroke rate of 0% to 3.5%, a cranial nerve injury rate of 5% to 39%, and overall mortality of 0% to 2.7%, with 15% of the patients unable to return to their preoperative daily activities.[30] With stereotactic radiosurgery, 60% of patients showed improvement in previous neurological deficits. Tumor control is obtained in 91% of the patients.[31] The Kaplan-Meier tumor control rate is 92.2% at 5 years and 86.3% at 10 years.[32] Hearing tends to worsen after radiosurgery; however, balance, dizziness, and tinnitus usually improve.[33]

Complications associated with glomus jugulare tumors include: Sigmoid sinus thrombosis Cranial neuropathies Pulsatile tinnitus Deterioration of hearing Vocal cord paralysis Aspiration Facial paralysis Conductive hearing loss Cerebrospinal fluid leak Lower cranial neuropathy Temporal bone osteoradionecrosis Brain radionecrosis

Glomus jugulare tumors require long-term surveillance. Follow-up necessitates collaboration of an interprofessional team that should include primary care physicians, neurosurgeons, otolaryngologists, and neuroradiologists. Other clinicians involved in rehabilitation and complications will also be part of the team, eg, physical medicine and rehabilitation physicians and physical therapists.

Long-term follow-up plays a critical role in the management of glomus jugulare tumors due to their slow-growing nature. Regular monitoring with serial imaging, including MRI with and without contrast, allows clinicians to detect tumor progression or recurrence early and adjust treatment strategies accordingly. For patients with a family history of paragangliomas, genetic screening offers an opportunity to identify high-risk individuals and facilitate early detection of multifocal disease.[4] Early identification and timely intervention reduce the risk of cranial nerve deficits, hearing loss, and other complications, ultimately lowering treatment-related morbidity and improving long-term outcomes. Patient education represents an essential component of effective management. Clinicians should provide comprehensive information regarding tumor behavior, potential symptoms, and the importance of adherence to follow-up schedules. Education should also address the genetic implications for affected families, including the availability of counseling and testing for at-risk relatives. Informed patients gain a better understanding of treatment options, potential risks, and expected outcomes, empowering them to participate actively in shared decision-making and to recognize early signs of tumor progression that warrant prompt evaluation.

Glomus jugulare tumors are rare, slow-growing paragangliomas of the skull base that often present with nonspecific symptoms such as tinnitus, hearing loss, or subtle cranial nerve deficits, making early diagnosis challenging. These tumors arise within the jugular foramen and can extend into the temporal bone, middle ear, and posterior fossa, potentially causing cranial neuropathies and vascular complications. Diagnosis relies on a combination of otoscopic evaluation, audiologic testing, high-resolution CT, MRI, and angiography, while treatment options include observation, surgical resection, preoperative embolization, fractionated radiotherapy, and stereotactic radiosurgery. Genetic screening for high-risk individuals may enable early detection, particularly in families with a history of paragangliomas, improving outcomes and reducing morbidity. Effective management of glomus jugulare tumors requires coordinated, interprofessional care. Physicians, including otolaryngologists, neurosurgeons, neuro-otologists, and neurologists, collaborate on diagnosis, treatment planning, and surgical intervention. Interventional neuroradiologists and endovascular specialists perform embolization and provide follow-up imaging, while radiation oncologists and medical physicists guide stereotactic radiosurgery. Nurses provide ongoing monitoring, patient education, and support for symptom management, while pharmacists ensure appropriate use of analgesics, antiemetics, and antibiotics during recovery. Clear communication, shared decision-making, and holistic care coordination optimize patient-centered outcomes, reduce complications, and improve team performance, ensuring patients receive timely, individualized, and safe care throughout diagnosis, treatment, and long-term follow-up.